The company has announced that all patients have completed treatment with SiPore15 in the STAR Trial
Development is well on track and top-line data will be reported in October this year, states the company in their press release.
SiPore15 is a first-in-class medical device using specially engineered mesoporous silica particles (MSP) to achieve a reduction in blood sugar – in both prediabetics and newly diagnosed type 2 diabetics.
“We are delighted to see that the collection of data in the STAR trial has progressed as planned and that we are on track for reporting results in October as already stated. No safety signals have been reported to date which continues to support the well-tolerated safety and tolerability profile we have observed in earlier clinical studies,” said Sana Alajmovic, co-founder and CEO of Sigrid Therapeutics.
Photo of Sana Alajmovic: Sigrid Therapeutics